Biotech | February 25, 2022
Biohaven licenses Taldefgrobep Alfa from Bristol Myers Squibb
It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).
It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).
Revotek announced that it has received clearance from the National Health Commission of China to begin a clinical study in the West China Hospital, Chengdu, with its first stem cell 3D bioprinting product, REVOVAS.
The transaction as well as the open offer is expected to be completed by June this year.
CEPI is accelerating its programme to develop broadly protective coronavirus vaccines—a core part of US $ 3.5 billion pandemic preparedness plan
Covaxin is a whole-virion inactivated Covid-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades
These programs are: Herpes simplex virus (HSV) vaccine candidate, Varicella-zoster virus (VZV) vaccine candidate and Checkpoint cancer vaccine.
The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines
Phase 2 clinical trial to begin in 2022 with participation by Cedars Sinai Medical Center, University of Utah, and City of Hope
Evonik invests in start-up to improve patient recovery after open-chest surgery
Resolv ER may remedy leading causes of blindness in adults
Subscribe To Our Newsletter & Stay Updated
